| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2021: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2020: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
|
|---|
| Outline of Final Research Achievements |
For therapeutic applications against defects of adult articular cartilage increase with aging, development of regenerative medicine and cartilage tissue engineering are important. However, autologous bone marrow mesenchymal stromal cell (MSC) implantation for elderly individuals is more difficult than young individuals, because capability of cell proliferation and differentiation of the cells decreases in elderly individuals. Cellular senescence contributes to organismal aging and age-related diseases. The p53 signaling network plays a critical role in the induction of cellular senescence. The human TP53 gene encodes twelve natural isoforms. Overexpressing Δ133p53, an anti-senescence p53 isoform, in near-senescent hMSCs and their differentiated chondrocytes showed characteristic differential expression genes in RNA-sequencing. We also obtained many Δ133p53-transcriptional target genes during the chondrogenic differentiation from Δ133p53-overexpressing hMSCs, by Cut & Run-sequencing.
|
